Abus Nasdaq 2020 - 04 - 24

Arbutus Biopharma Corporation

ABUS | $2.76 0.36% 92K

(0.0% 1d) (10.4% 1m) (8.7% 1y) (0.0% 2d) (4.2% 3d) (0.0% 7d) (47.14% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 495,398,469
http://www.arbutusbio.com
Sec Filling | Patents | 80 employees

(US) Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

hepatitis injection

add to watch list Paper trade email alert is off

Press-releases

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
Published: 2024-04-18 (Crawled : 12:00) - globenewswire.com
ABUS | $2.76 0.36% 92K

Health Technology

| -5.82% | O: -5.82% H: 0.0% C: 0.0%
first report update financial results

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
Published: 2024-04-04 (Crawled : 12:30) - globenewswire.com
MRNA | News S | $107.16 -0.68% 1.7M

Health Technology

| 6.6% | O: 1.46% H: 3.2% C: -0.41%
ABUS | $2.76 0.36% 92K

Health Technology

| 9.56% | O: 16.73% H: 6.14% C: 2.39%
patent construction biopharma ongoing

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
ABUS | $2.76 0.36% 92K

Health Technology

| 8.7% | O: -1.58% H: 3.05% C: 2.41%
year update financial results

Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
Published: 2024-03-18 (Crawled : 14:00) - prnewswire.com
CVAC | $2.36 -9.23% 430K

Health Technology

| -21.21% | O: 0.0% H: 0.0% C: -2.73%
BNTX | News | $88.55 0.07% 62K

Health Technology

| -4.31% | O: 0.48% H: 1.18% C: 0.08%
ABUS | $2.76 0.36% 92K

Health Technology

| 4.96% | O: 0.38% H: 0.38% C: -3.42%
report genomic market

Arbutus to Participate in Two Upcoming Investor Conferences
Published: 2024-03-08 (Crawled : 12:30) - globenewswire.com
ABUS | $2.76 0.36% 92K

Health Technology

| 0.0% | O: 0.18% H: 0.0% C: 0.0%

Arbutus to Participate in Two Upcoming Investor Conferences - March 8, 2024
Published: 2024-03-08 (Crawled : 14:30) - biospace.com/
ABUS | $2.76 0.36% 92K

Health Technology

| 0.0% | O: 0.18% H: 0.0% C: 0.0%

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Published: 2024-02-29 (Crawled : 12:30) - globenewswire.com
ROIV | $10.835 -0.96% 500K

Manufacturing

| -6.58% | O: 1.2% H: 0.34% C: -3.46%
ABUS | $2.76 0.36% 92K

Health Technology

| -5.5% | O: -1.37% H: 0.0% C: -2.44%
year update financial results

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
Published: 2024-02-15 (Crawled : 12:30) - globenewswire.com
ABUS | $2.76 0.36% 92K

Health Technology

| -5.98% | O: 0.85% H: 0.0% C: -1.36%
report year update financial results

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
ABUS | $2.76 0.36% 92K

Health Technology

| 14.11% | O: 3.32% H: 3.21% C: -1.61%
update financial

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
ABUS | $2.76 0.36% 92K

Health Technology

| 52.78% | O: 1.67% H: 0.0% C: -3.28%
hbv003 biopharma collaboration trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001447028-24-000029	4	2024-02-06	2024-02-01	Buy	A	380500	380500
0001447028-24-000029	4	2024-02-06	2024-02-01	Buy	A	95100	95100
0001447028-24-000028	4	2024-02-06	2024-02-01	Buy	A	403900	403900
0001447028-24-000028	4	2024-02-06	2024-02-02	Sell	S	4358	125542
0001447028-24-000028	4	2024-02-06	2024-02-01	Buy	A	101000	129900